ALDX.US Aldeyra The

Healthcare Biotechnology USA Stocks
0.6438 USD
Close of Nov 14, 2026
0.5270 5.93
Market cap
USD 38.9M
P/E
-
P/B
1.08x
ROE
0.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALDX.US undervalued?

Graham number

The Graham number of Aldeyra The cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aldeyra The fundamental analysis

No fundamental analysis for Aldeyra The yet.

Aldeyra The stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aldeyra The

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-…

Full company profile